Reported Earnings • Aug 16
Second quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2026 results: US$1.33 loss per share (improved from US$3.18 loss in 2Q 2025). Revenue: US$331.8k (down 19% from 2Q 2025). Net loss: US$4.47m (loss narrowed 2.5% from 2Q 2025). Revenue missed analyst estimates by 55%. Earnings per share (EPS) exceeded analyst estimates by 5.0%. Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 7.6% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings. Major Estimate Revision • Aug 14
Consensus EPS estimates fall by 10% The consensus outlook for fiscal year 2026 has been updated. 2026 expected loss increased from -US$4.53 to -US$5.00 per share. Revenue forecast of US$3.77m unchanged since last update. Medical Equipment industry in the US expected to see average net income growth of 13% next year. Consensus price target up from US$63.33 to US$80.00. Share price fell 14% to US$2.29 over the past week. Announcement • Aug 13
Femasys Inc. Expands Global Patent Protection for Fembloc with Issuance of Blended Polymer Patents Femasys Inc. announced the issuance of patents in the United States and key international markets that expand intellectual property protection for the blended polymer component of FemBloc, the Company’s non-surgical permanent birth control technology. These patents broaden and extend FemBloc’s global intellectual property protection, complementing existing patents covering its delivery system and further strengthening the technology’s competitive position in a highly regulated market with rigorous clinical and regulatory requirements. FemBloc is approved for marketing in Europe and other select international markets and remains investigational in the United States. FemBloc is a first-of-its-kind, non-surgical solution for permanent birth control, addressing a significant unmet need in women’s reproductive health. The technology combines a patented delivery system with a separately patented blended polymer that is placed into both fallopian tubes, safely degrades and forms natural scar tissue for permanent occlusion. Unlike surgical sterilization, FemBloc requires no anesthesia, incisions or recovery time, offering women a more convenient and affordable alternative while avoiding risks associated with surgery. The newly issued patents protect FemBloc’s blended polymer component in the United States (US Patent No. 12606719), Japan (JP Patent Nos. 7379157 and 7594647), South Korea (KR Patent No. 10-2713236), Brazil (BR Patent No. 1120190157140), Hong Kong (HK Patent No. HK40018048), India (IN Patent No. 430804), and multiple European countries (based on EPO Patent No. 3579890), including Belgium, Denmark, Germany, France, Ireland, Spain, Great Britain, Italy, Luxembourg, the Netherlands, Sweden, Turkey and Switzerland. Together with existing patents covering the delivery system, these patents broaden and extend intellectual property coverage for FemBloc across key global markets. Femasys is also advancing FemBloc, its non-surgical, in-office permanent birth control solution, toward U.S. FDA approval through the ongoing FINALE pivotal trial (NCT05977751). FemBloc received regulatory approvals in Europe, the UK and New Zealand in 2025, supporting commercialization through strategic partnerships in select international markets. Femasys’ portfolio is supported by broad intellectual property protection and clinical data demonstrating favorable safety, encouraging effectiveness results, and high patient and practitioner satisfaction. 
